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Abstract
Currently, immunosuppressive therapy in kidney transplant recipients is generally performed by 
protocols and adjusted according to functional or histological evaluation of the allograft and/or 
signs of drug toxicity or infection. As a result, a large fraction of patients are likely to receive too 
much or too little immunosuppression, exposing them to higher rates of infection, malignancy and 
drug toxicity, or increased risk of acute and chronic graft injury from rejection, respectively. 
Developing reliable biomarkers is crucial for individualizing therapy aimed at extending allograft 
survival. Emerging data indicate that many assays, likely used in panels rather than single assays, 
have potential to be diagnostic and predictive of short and also long-term outcome.
While numerous cross-sectional studies have found associations between the results of these 
assays and the presence of clinically relevant post-transplantation outcomes, data from prospective 
studies are still scanty, thereby preventing widespread implementation in the clinic. Of note, some 
prospective, randomized, multicenter biomarker-driven studies are currently on-going aiming at 
confirming such preliminary data. These works as well as other future studies are highly warranted 
to test the hypothesis that tailoring immunosuppression on the basis of results offered by these 
biomarkers leads to better outcomes than current standard clinical practice.
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Introduction
Measuring immunosuppressive drug levels in blood is the most frequently used tool to 
monitor transplant immunosuppression. However, even stringent obedience to the 
recommended drug levels (frequently chosen on empiric bases) does not prevent either 
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overimmunosuppression resulting in infections and malignancies or 
underimmunosuppression associated with an increased risk of acute rejection or chronic 
immune injury of the graft. Indeed, different genetic background may result into different 
immune reactivity across patients despite similar levels of immunosuppressive drugs in the 
blood [1, 2]. Acute rejection is suspected when serum creatinine increases without signs of 
dehydration, drug toxicity, or urological complication and, most importantly, it usually 
increases when overt allograft injury has already occurred. Knowing blood levels of 
immunosuppressive drugs is helpful, but is usually insufficient per se to differentiate 
rejection from toxicity, thus necessitating biopsy. Hence, identification of biomarkers of 
immune reactivity is a true priority in transplantation research and development of strategies 
for immune monitoring will be crucial for distinguishing transplant recipients who will 
benefit from a reduction in, or even the withdrawal of, immunosuppression from those who 
require more intense, lifelong immunosuppression. Finally, some of these assays may be 
useful biomarkers not only of acute rejection but of long term outcomes which are 
increasingly dissociated from the excellent results achieved in the first three years after 
transplantation. This review provides an overview of the most promising biomarkers to 
quantify alloreactivity.
T cell alloreactivity
Development of T cell alloreactivity biomarkers starts with the understanding of anti-donor 
T-cell immunity. There are two main pathways of HLA alloantigen recognition: the direct 
and the indirect pathway. The ‘direct’ pathway requires the recognition of intact donor HLA 
alloantigens on the surface of donor cells, whereas the ‘indirect’ pathway of HLA 
allorecognition involves the internalization, processing, and presentation of alloantigens as 
peptides bound to recipient HLA molecules [3, 4]. Since professional donor antigen 
presenting cells (APCs) disappear after the first weeks or months after transplantation, 
priming by the direct pathway has classically been thought to be important for the 
pathogenesis of acute rejection in the early post-transplantation period [5-7]. Priming via the 
indirect pathway has long been considered to play a pathogenic role in late graft failure 
[8-10], but recent studies suggest that both pathways persist during the entire life of the graft 
and can contribute to the pathogenesis of chronic injury, as direct recognition of donor 
alloantigens in recipient professional APCs may also occur via the so called third or semi-
direct pathway [11, 12].
A set of assays has been developed to quantify T cell alloreactivity. Measurement of the 
primary in vitro response to direct recognition of allogeneic molecules occurs in the mixed 
lymphocyte reaction (MLR), in which recipient T cells are tested for reactivity to donor 
cells. In an MLR, peripheral blood lymphocytes from two individuals are mixed together in 
tissue culture for several days; donor lymphocytes are inactivated, thereby allowing only the 
recipient lymphocytes to proliferate in response to foreign histocompatibility antigens (one-
way MLR) (Table 1 and Figure 1) [13]. This reaction was first described in the 1960s using 
3Hthy incorporation as a read-out, and has been extensively used to study anti-donor T cell 
responses. Low levels of T cell expansion are considered a sign of over-immunosuppression, 
whereas high T cell expansion in response to donor antigens is read as increased risk of 
allograft rejection. In 19 recipients of cadaveric renal allografts, donor-specific hypo-
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responsiveness assessed by MLR at 3 and 6 months after transplantation was associated with 
a better graft outcome at 1 year [14]. However, in this conventional form, MLR is poorly 
reproducible and has a limited predictive value in clinical transplantation [15].
Different assays and alternative readouts have been developed to obtain information 
regarding immunological responses that are of further clinical utility. Most assays test the 
direct alloreactivity pathway, but modifications in culture conditions can be made for almost 
all assays to measure indirect pathway responses (Figure 1).
Alloreactive T-cell Enzyme-linked immunosorbent Spot (ELISPOT) assay
Among notable advances in transplantation immunology research is the recognition that a 
great proportion of the alloreactive T cell repertoire derives from the memory pool [16], as 
the hallmark of adaptive immunity, whose unique properties indicate that they may be 
detrimental to transplant outcome [17, 18], and consequently, measurements of memory 
alloimmunity could be used as biomarkers for post-transplantation outcomes. Frequencies of 
donor-reactive memory T cells are detectable by cytokine enzyme-linked immunosorbent 
Spot (ELISPOT). This assay combines the features of the MLR with the concept of an 
ELISA assay (Table 1 and Figure 1). Recipient peripheral lymphocytes are cultured in the 
presence of inactivated donor or third-party cells in tissue culture wells coated with a capture 
antibody against the cytokine of interest. The ELISPOT plates are then incubated for 18–24 
h to allow responding cells to recognize alloantigens and to release cytokines, which are 
captured directly at their source of secretion, before they are diluted, degraded, or absorbed 
by receptors on nearby cell surfaces. The spot that develops represents a cell that had been 
primed to the stimulating antigen(s) in vivo. To increase reproducibility of the assay and 
reduce the time associated with visual counting, computerized plate readers using digital 
cameras have been developed. Thus, ELISPOT provides a measure of the frequency of 
previously activated or memory T cells that respond to specific antigens by producing a 
selected cytokine [19].
ELISPOT has been found to be predictive of poor graft function. In 55 kidney transplant 
recipients, IFN-γ ELISPOT levels during the first 6 months after surgery correlated 
significantly with graft function at 6 and 12 months following transplantation [20]. Multiple-
regression analyses indicated that the correlations between the early ELISPOT 
measurements of IFN-γ and serum creatinine were independent of acute rejection, delayed 
graft function or the presence of panel-reactive antibodies before transplantation [20]. 
Similar results were reported by a subsequent study in 23 kidney transplant recipients, 
showing that pre-transplantation anti-donor IFN-γ ELISPOT had a significant inverse 
correlation with allograft function at 6 and 12 months [21].
Pre-transplantation measurements of recipient T-cell alloreactivity to donor antigen via the 
IFN-γ ELISPOT assay are consistently correlated with acute rejection after kidney 
transplantation. The first study to evaluate this assay reported that 7 of 9 kidney transplant 
recipients with pre-transplantation donor-specific IFN-γ spots ≥ 25/300,000 cells had acute 
rejection after transplantation, while none of 10 recipients with < 25 spots per 300,000 cells 
developed acute rejection [22]. In a larger cohort of 37 African-American recipients of 
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deceased donor transplants with pre-transplantation testing, 50% of IFN-γ ELISPOT 
positive recipients had a biopsy-proven acute rejection versus only 17% of IFN-γ ELISPOT 
negative recipients [23]. Expanding on this experience, the same group reported the 
association between a positive pre-transplantation IFN-γ ELISPOT response and acute 
rejection in a separate, larger cohort of 100 kidney transplant recipients [24]. This 
association was independent of HLA matching, delayed graft function, donor source, 
ethnicity, and dialysis vintage [24]. In studies outside of the United States, Nickel et al. 
described a correlation between acute rejection and pretransplantation IFN-γ ELISPOTs in 
42 German patients [25], and others have described similar findings in Spanish, Korean and 
Polish kidney transplant recipients [26-28]. ELISPOT has also potential utility in the 
identification of patients who may benefit the most from antibody induction therapy. In a 
retrospective analysis of 130 kidney transplant patients, individuals with higher pre-
transplantation ELISPOT levels were at increased risk of acute rejection. However, patients 
with high ELISPOT levels who received antibody induction therapy (anti-CD25 or 
thymoglobulin) had a significantly lower risk of acute rejection than their counterparts who 
did not received induction. Post-transplant conversion to a negative ELISPOT assay occurred 
in 86% of patients who received induction therapy vs. 35% of patients who did not [29]. A 
subsequent study from the same group showed that thymoglobulin induces a prolonged 
reduction in anti-donor IFN- ELISPOT response, whereas anti-CD25 depleting antibodies 
do not affect it [30]. In a similar retrospective analysis in 90 consecutive kidney transplant 
individuals, pre-transplant T-cell alloreactive patients showed a significantly higher risk of T-
cell mediated rejection during the early period of time after transplantation. Likewise, this 
effect was particularly evident in patients not receiving T-cell depletion induction therapy 
[31].
Contrary to previous reports, the large Clinical Trials in Organ Transplantation-01 
observational study failed to identify an association between pretransplant IFN-γ ELISPOT 
positivity and the incidence of acute rejection or estimated glomerular filtration rate (eGFR) 
at 6- or 12-month in 176 primary kidney transplant recipients treated with heterogeneous 
immunosuppression [32]. Secondary analyses showed that, in patients not induced with 
thymoglobulin, positive pre-transplant-ELISPOT was associated with lower 6- and 12-month 
eGFRs than negative IFN-γ ELISPOT. In contrast, IFN-γ ELISPOT status did not correlate 
with posttransplant eGFR in subjects given thymoglobulin, which suggests that 
thymoglobulin may reduce the immunogical risk of patients with high pre-transplant IFN-γ 
ELISPOT.
Given evidence suggesting that ELISPOT may quantify recipient risk for rejection, it has 
been used to tailor immunosuppression in 60 kidney transplant patients in a non-randomized 
pilot study, who were allocated to a calcineurin inhibitor-based or a calcineurin inhibitor-free 
immunosuppressive regimen on the basis of pre-transplantation “high” vs. “low” anti-donor 
IFN-γ ELISPOT assays, respectively [33]. High pre-transplant ELISPOT levels were 
frequent even in the absence of anti-HLA antibodies and represented a major risk factor for 
acute rejection and graft dysfunction, despite the use of more potent immunosuppression 
with calcineurin inhibitors. Though further investigations are needed, this study suggests that 
evaluating antidonor T-cell sensitization before transplantation may help define 
immunosuppressive regimens on a single patient basis.
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The ELISPOT procedure takes 24-36 hours, which makes it less suitable to assess the pre-
transplant immunological risk in deceased donor recipients. To address this issue and that of 
patients with no donor cell availability as well as to provide information on the overall T cell 
immunoreactivity of transplant patients, a T-cell reactivity index (panel of reactive T-cells, or 
PRT) based on the frequency of positive ELISPOT responses using a pool of donor antigens 
prior to transplantation that may be reflective of potential organ donors was reported 
simultaneously by 2 groups [34, 35]. Similar to the panel-reactive antibody (PRA) test for 
identifying individuals with elevated levels of anti-HLA antibodies, the PRT may identify 
patients at risk for post-transplantation cellular immune-mediated graft injury. In a small 
study of 30 kidney transplant patients, six of the seven (86%) patients with acute rejection 
were PRT-positive whereas only one had low PRT before transplantation [36].
A recent study by the Fairchild group showed that a significant subpopulation of alloreactive 
memory CD28−CD8+T cells are not detected by the above-noted approaches [37-40]. 
Addition of IL-15 to the cultures rescues the proliferating capacity of these cells, making 
them detectable [41]. Since renal epithelial cells are able to produce IL-15 during 
inflammation, quantification of these cells might be relevant in quantifying the immune risk 
of kidney transplant recipients. Future investigations using MLR and ELISPOT should 
therefore consider the addition of IL-15 to cultures to assess this population of memory cells 
and their contribution to graft injury.
Monitoring indirect alloreactivity
Most of the aforementioned assays are designed to evaluate the direct alloimmune response. 
However, evidence that indirect alloreactive CD4+ T cells are the only cells that can provide 
help to alloreactive B cells in animal models, leading to the formation of anti-HLA 
antibodies, prompted an increased interest in the development of novel assays capable of 
quantifying this pathway [42, 43]. Costs and complexity of the procedures, however, make 
the assessment of indirect alloresponses more challenging. Three approaches to address the 
indirect alloimmune response include: peptides from polymorphic regions of HLA, lysates 
of donor cells, and non-polymorphic peptides.
By using peptides from polymorphic regions of HLA, a cross-sectional study of 45 kidney 
transplant patients showed that increased IFN-γ ELISPOTs in both the direct and indirect 
pathways were associated with abnormal graft function [44]. This method has higher 
reproducibility, and other retrospective and cross-sectional studies have shown similar 
results [45-47], but no prospective study has been done yet. Moreover, this approach is 
challenged by the difficulties of creating large libraries of peptides to encompass the wide 
number of HLA polymorphisms.
An alternative approach is the use of donor cell lysates or fragments, which in theory should 
allow the use of for the testing of the full repertoire of alloantigen available. A study in mice 
showed that donor cell lysates generated through cell freezing and thawing were able to 
induce a T cell response in skin transplanted animals through the indirect pathway [48]. A 
similar approach was tested in humans by measuring the IFN-γ production of PBMC from 
kidney transplant patients with or without chronic rejection in response to donor cells 
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undergone through multiple cycles of freezing and thawing [8]. Indirect response 
alloreactivity was significantly lower in stable patients as compared to those with chronic 
rejection, a difference that was not captured by evaluating only the direct pathway. In 
another cross-sectional study of 34 longstanding living donor renal transplant recipients, 
indirect response IFN-γ ELISPOT against donor-cell fragments correlated with proteinuria, 
a major predictor of graft failure [11]. However, to date, no prospective studies have been 
done to validate this approach.
Alloimmune responses are frequently associated with intramolecular epitope spreading, and 
in experimental models, this includes responses to cryptic self-epitopes [46, 49]. In support 
of this concept, a cross-sectional study in 110 kidney transplant recipients showed that IFN-
γ production by PBMC stimulated with nonpolymorphic HLA-derived peptides was 
associated with chronic rejection [50]. The assessment of responses to such peptides might, 
therefore, be used to provide evidence of alloimmunization without the need to account for 
donor or recipient HLA type, provided they reflect an immune response initiated by 
alloantigen that drives allograft injury. This does not even require that the peptide tested are 
allogeneic, because the response to “cryptic self-epitopes” could equally meet these criteria 
[51, 52]. As with the other approaches above, however, prospective studies are lacking, and 
will be required to validate the utility of these assays in the prediction of allograft outcomes.
Characterizing Regulatory T cells
Regulatory T cells (Treg) consist of a heterogeneous population of T cells with the ability to 
suppress immune responses. It has long been established that Foxp3 is the major 
transcription factor that determines the fate, identity, and function of Treg, and Treg regulate 
immune functions by producing cytokines such as TGF-β, IL-10, and IL-35 [53, 54]. 
However, there are subsets of Treg that do not express Foxp3. For example, TGF-β–
producing Th3 and IL-10–secreting Tr1 Treg also can be potent suppressors in some 
experimental systems. Given the vast evidence demonstrating the contribution of Tregs 
regulating immune responses in different animal models, great hopes have flourished on the 
potential use of Tregs as markers of tolerance, transplant rejection, or prediction of graft 
outcomes.
However, while murine studies consistently showed a relationship between increased 
numbers of FoxP3+ Tregs and tolerance [55], the induction of CD25 and FoxP3 upon 
activation of human Teffs has led to far more variable clinical data [54]. Findings of reduced 
numbers of Tregs in patients with acute or chronic rejection have not been consistent [50, 
56-61], nor have findings of increased numbers of Tregs in tolerant recipients [56, 62-64]. 
Despite the growing list of markers useful for identifying human Tregs, none is able to 
clearly identify T cells with suppressive capacity. Thus, pure enumeration of 
immunophenotypic Tregs needs to be accompanied by an assessment of Treg suppressive 
function. Using autologous cells as responders in Treg assays of kidney transplant patients 
can be misleading, since immunosuppression can decrease their proliferative capacity, which 
may explain why Tregs from patients with rejection had impaired suppressive function in 
some studies but not others [58, 60, 61, 65, 66]. To address this issue, Akimova et al. 
developed a standardized suppression assay where CD25+CD127lowCTLA4+ FoxP3+ Treg 
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function was tested against a Teff cell from healthy individuals, so that Tregs are the only 
variable. By using this strategy, they found that patients with tacrolimus levels >3.6 ng/mL 
had weaker Treg function than those with levels <3.6 ng/mL, whereas rapamycin therapy 
positively correlated with Treg numbers and their expression of CTLA4 [67]. Whether this 
new strategy to quantify Treg activity correlates with the risk of developing acute rejection is 
still unknown. Following a similar approach to an MLR, Canavan et al. developed a 7-hour 
flow-cytometric assay to assess regulatory T cell (Treg) suppressive function, by measuring 
CD154 and CD69 expression on T effector cells (Teff) in a suppression assay (Figure 1) 
[68]. Expression levels of these markers correlated excellently with gold-standard assays 
involving inhibition of CFSE dilution and cytokine production. This test could allow rapid 
evaluation of Treg suppressive function in clinical trials of cell therapy, enabling the 
translation of the large body of preclinical data from bench to bedside. Analysis of the 
epigenetic status (e.g degree of methylation) of FoxP3 can also provide helpful information 
on the suppressive function of Tregs. An additional way to characterize the suppressive 
function of Tregs is to measure the ratio between Teff/Treg. Lower values have been 
associated with better graft outcomes [69]. Together, these assays provide a new approach to 
monitor the immune status of transplant patients. However, no existing evidence suggests 
that measuring Treg activity can predict the risk of future acute/chronic rejection or 
infections. Similarly, conflicting evidence exists regarding an increased Treg presence in 
transplant patients with cancer, but the cross-sectional nature of the data prevents any 
analysis on the predictive power of such a parameter [70]. The entire picture may be 
complicated by evidence that increased Tregs associated with rapamycin are associated with 
higher risk of acute and chronic rejection and lower risk of tumors compared to 
cyclosporine, possibly secondary to differential effects of the two drugs on effector T and 
actively proliferating tumor cells [71, 72]. Ad hoc prospective studies are therefore needed 
to validate the utility of Treg characterization in the management of transplant patients.
B cell alloreactivity
The effector role of alloantibodies was already shown in the 1960s with the observation of 
the occurrence of hyperacute rejection in many sensitized transplant patients [73]. Even 
though the issue of hyperacute allograft rejection has been almost overcome by the 
introduction of novel crossmatch techniques [74], and more sensitive assays measuring the 
presence of circulating anti-HLA antibodies both before and also after transplantation [75], 
the persistence of humoral immunity against donor antigens still remains as the main cause 
leading to allograft rejection in the mid/long term.
Even though the assessment of circulating anti-HLA antibodies has significantly improved 
with the advent of novel highly sensitive assays, which have allowed a better understanding 
of the risk and impact of humoral immunity in kidney transplantation [75], the solely focus 
on circulating anti-HLA antibodies to determine the allosensitization state of a given 
transplant patient may underestimate the magnitude of the complete humoral immune 
response as it excludes the detection of the entire mBC pool. There are two major B-cell 
populations that contribute to the maintenance of immunological memory: long-lived plasma 
cells (LLPC) and memory B cells (mBCs); whereas the former reside primarily in the bone 
marrow where they continuously secrete antibodies that act rapidly on invading microbes 
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and are responsible of the maintenance of serum antibody levels, the latter are mainly 
located in peripheral lymphoid tissues and can, upon re-encounter with the priming antigen, 
differentiate into antibody-secreting cells (ASCs) and thus amplify the antibody response 
while also replenishing the pool of long-lived plasma cells to maintain long-term antibody 
levels in the absence of pathogen [76, 77]. A key element that distinguishes antibody-
producing LLPC and mBC from activated naïve B cells is that they have both undergone 
class switching and somatic hypermutation in germinal centers [78], although in some 
settings mBC may lack these differential features [79]. Of note, mBCs may exist in the 
absence of detectable serum antibody levels and their rapid differentiation and antibody 
production may be of high relevance for a protective humoral response [80, 81].
Indeed, in the transplant setting, HLA-sp antibodies may appear and disappear in several 
situations such as after undergoing transplantectomy [82], re-transplant patients display 
worse allograft outcomes regardless of preformed DSAs [83] and highly suggestive 
histological lesions of humoral rejection are frequently observed despite no DSAs [84]. 
Therefore, the detection of functionally active anti-donor HLA-sp mBCs at in the context of 
transplantation could provide additional relevant biological information regarding the 
sensitization state of transplant candidates besides the accurate evaluation of circulating 
alloantibodies.
Recent relevant technical approaches have focused in tracking mBC using novel in vitro 
assays in the context of solid organ transplantation (table 2).
Quantification of HLA-specific mBC using Flow cytometry
Taking advantage of the introduction of the HLA tetramer technology to quantify antigen-
specific T cells, Mulder and co-workers using either human B cell hybridomas [85] and 
HLA-specific B cells from pregnancy-immunized individuals [86], were the first to show the 
feasibility of tracking HLA-specific B cells binding epitopes of foreign HLA molecules in 
their original conformation through their B-cell receptor (BCR). This technology uses 
streptavidin-biotin complexes of HLA molecules conjugated to a fluorescent protein. Then, 
the tetramer-binding B cells can be accurately enumerated by flow cytometry and allow a 
rapid quantization of the B-cell response to the given HLA antigen. Zachary et al. [87, 88] 
added CD27 and CD38 markers to discriminate the tetramer-binding mBc and plasma cells, 
respectively. Interestingly, a high frequency of HLA-tetramer mBc was found in negative 
DSA patients at the time of transplantation that subsequently developed DSA after 
transplantation suggesting the presence of donor-specific mBc already prior to transplant 
surgery. This feature was particularly evident among patients that did not receive B-cell 
depletion therapy with rituximab [89]. A main drawback of such technique that should not 
be obviated is that a significant number of B cells, which can be up to 6% of total CD19+ B 
cells, may recognize non-HLA fractions of the tetramer, such as the streptavidin-
phycoerythrin, leading to nonspecific staining [90]. Hence, more controls must be done such 
as using immunomagnetic depletion with streptavidine beads before staining or use similar 
tetramers conjugated to two different fluorochromes [86]. Importantly, while this technique 
allows for easy quantification HLA-specific B cells harboring a HLA-specific BCR using 
flow cytometry readouts, it does not really enumerate frequencies of HLA-specific mBC 
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capable of releasing antibodies. Furthermore, it bears low sensitivity for the detection of low 
level of responses, which is most likely the case when measuring mBC responses. In a 
similar new approach but using HLA-coated multiplex beads, circulating HLA bead-B-cell 
frequency and specificity might be also analyzed using flow cytometry (Ahmed Akl, 
Roitberg-Tambur, M Javeed Ansari, Abstract OR07 ASHI 2014). In a small cohort of kidney 
transplant patients, this group showed that transplant patients with poor graft outcome and 
circulating alloantibodies showed significantly higher frequencies and polyreactivity against 
both class I and II HLA antigens as compared to patients with good graft outcomes.
Assessment of anti-HLA antibodies in supernatants of ex vivo expanded mBC cultures
Since antigen-specific ASCs do not generally circulate in the periphery, but only transiently 
early after active or accidental immunization, and antigen-specific mBc do not secrete 
antibodies, in vitro differentiation of circulating mBc onto an ASC-like phenotype capable 
of secreting antibodies can be achieved by using a number of different antigen-independent 
polyclonal activation methods [91]. Most activator protocols generally include different 
stimuli. Most common antigen-independent activators used are CpG (a Toll-like receptor 
[TLR] 9 agonist), pokeweed mitogen (PWM) and Staphylococcus aureus Cowan (SAC) 
often combined with CD40-ligand (CD40L) and/or cytokines such as interleukin (IL-) 2 and 
IL-10 [92]. More recently, the use of the TLR7/TLR8 agonist R848 plus IL-2 was also 
shown to efficiently activate and differentiate mBc onto ASCs [81, 91]. Of note, to 
efficiently obtain sufficient ASC numbers, 5 to 7 days of in vitro stimulation either purified 
B cells or PBMCs are required.
A first attempt to evaluate the presence of HLA-specific mBc was carried out by Han and 
colleagues [93] after assessing alloreactive IgG antibodies in the supernatant of ex vivo 
expanded mBc cultures using solid-phase assays . By analysing the presence of anti-HLA 
antibodies of expanded mBc culture supernatants in a small group of transplant patients, 
transfusion-derived sensitized individuals as well as multiparous women with serum HLA 
antibodies, they observed that HLA-specific antibodies were detected in sensitized 
individuals, but not in the non-sensitized controls and furthermore, most transplant patients 
did also show antibodies against mismatched donor HLA antigens. Most interestingly, DSAs 
were found in some B-cell cultures but not in concomitant serum of the patients, illustrating 
that such DSAs were released by circulating mBc rather than by LLPC. In a recent 
interesting report using the same method for tracking HLA-specific mBc, Snanoudj et al. 
[94] depicted the presence of HLA-sp antibodies in expanded mBC culture supernatants in a 
high proportion of highly sensitized patients, showing a high burden of previous allogeneic 
sensitization, even long time after first allogeneic contact. In addition, the authors described 
a more restricted epitope reactivity of mBC antibodies as compared with circulating HLA-sp 
antibodies, suggesting that particular antigens eliciting strong immune responses are most 
likely responsible to induce and maintain circulating alloreactive mBCs over time. While 
this method seems a feasible approach to potentially translate to the clinic practice for 
questioning the mBc compartment, it has two main caveats: 1) it does not quantify the 
frequency of HLA-specific IgG-producing mBc in a funcitonal manner and 2) the relatively 
low frequencies of HLA-specific antibodies found in some expanded mBc cultures might 
lead to false negative results, regardless the use of highly sensitive solid-phase assay 
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platforms. Indeed, in a recent study done by our group (Bestard O et al., manuscript in 
preparation), the comparison between MFI values of HLA-specific antibodies assessed in 
either the serum or supernatants of expanded mBc cultures of the same individual as 
compared to circulating HLA-specific mBc frequencies against the same HLA antigen using 
a highly sensitive B-cell ELISPOT assay, revealed that while some alloantibodies and mBc 
frequencies could be simultaneously detected using all 3 approaches, some others were not 
found either in the serum or in the supernatants, whereas could be clearly enumerated when 
using a B-cell ELISPOT assay (Figure 2) thus, highlighting the higher sensitivity of the 
latter method to detect HLA-specific mBc responses. Furthermore, although alloantibody 
titers of these supernatants can be extrapolated to the total numbers of circulating mBC, this 
quantification differs from reality as it assumes that all ASCs secrete a constant amount of 
alloantibodies.
HLA-specific B-cell Enzyme-linked Immunosorbent Spot (ELISPOT) Assays
To accurately quantify the frequency of HLA-specific mBc, the most sensitive technical 
approach is to use a B-cell enzyme-linked immunosorbent spot (ELISPOT) assay platform. 
This assay was first described in 1983 by Czerkinsky et al [95] and has proven to be an 
important method for the detection of IgG-producing B cells. The assay has also been 
further developed for the detection of antigen-specific plasma blasts and mBc [77, 96, 97]. 
Recently, our group showed the capacity of the B-cell ELISPOT to accurately enumerate 
cytomegalovirus (CMV)-specific mBC frequencies within kidney transplant patients [98]. 
We demonstrated the high sensitivity of the assay to measure low frequencies of CMV-
specific mBC in peripheral blood, even in transplant patients without anti-CMV IgG 
antibodies in the sera, and showing higher protection against viral infection. A first report in 
the context of pediatric heart transplantation using this assay was done by Fan et al, 
evaluating the frequency of ABO-specific antibody-producing B cells [99], demonstrating 
the immune B-cell tolerance state of this setting. Next, Perry et al. studied the presence of 
HLA-specific IgG-producing bone marrow–residing plasma cells obtained from bone 
marrow aspirates as well as from peripheral blood [100] and confirmed that most ASC 
reside exclusively in the bone marrow. A first attempt aiming at quantifying circulating 
HLA-specific mBC frequencies in the context of kidney transplantation using a B-cell 
ELISPOT was done by Heidt and colleagues [101]. For this purpose, they polyclonally 
activated during 7 days, isolated peripheral blood B cells in a CD40-driven culture system 
using either a complex L-CD40L cells or a more accessible anti-CD40 mAb in combination 
with a cytokine concktail consisting of interleukin (IL)-2, IL-10, IL-21, and CpG DNA 
[102]. After such an activation protocol, B cells are transferred to streptavidin precoated 
ELISPOT plates, followed by biotinylated synthetic HLA class I or II molecules. In these 
initial studies they showed the feasibility of the assay to accurately detect low frequencies of 
HLA-specific mBc frequencies both in some pregnancy-immunized women as well as in a 
small group of kidney transplant patients against previously exposed HLA antigens, which 
were harbored in previous kidney allografts. More recently, our group developed a novel B-
cell ELISPOT assay approach based on a cellular stimulation culture method based on the 
TLR 7/8 agonist R848 and IL-2 [103] and tested it in a large group of 70 highly HLA 
sensitized patients as well as in kidney transplant individuals. Differently from previously 
reported HLA B-cell ELISPOT methods, our approach allowed for using PBMCs rather than 
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sorted B cells. In addition, as frequencies of HLA-sp mBCs are relatively low, multimerized 
class I and class II HLA molecules were used, enabling clear detection of very low IgG-
producing mBC frequencies. In this study, we confirmed that mBC frequencies against both 
class I and class II HLA antigens may be detected in peripheral blood in patients with 
obvious allogeneic sensitization background, even in the absence of detectable circulating 
anti-HLA antibodies. Remarkably, we described that high frequencies of d-s alloreactive 
mBCs are present in kidney transplant patients during ABMR and also before 
transplantation, reflecting an active baseline anti-donor sensitization state not always 
depicted by circulating DSA. Differently from a previous report published by Lynch et al 
[104] using a complex B-cell ELISPOT assay procedure based on cultured isolated donor 
fibroblasts to obtain a broader donor antigen repertoire, we did not find a universal detection 
of alloantigen mBC responses in all patients after transplantation. Currently, two large 
European observational studies (Leiden, Holland and Barcelona, Spain) are currently 
ongoing to assess the value of quantifying HLA-specific mBC in kidney transplantation. 
However, the 6-day cell culture and the use of cells as the biological specimen to analyze are 
major hurdles that may limit its implementation in the clinical practice. Furthermore, the 
need of the whole HLA antigen repertoire to be tested in these assays is also highly needed 
in order to cover all potential donor-recipient HLA mismatches of all transplant candidates 
around the globe. Similarly to the T-cell ELISPOT assay, these assays should undergo 
interlab validation within experienced laboratories and prospective large, observational trials 
are also warranted in order to obtain consistent data. These studies should be developed 
within international research networks in close collaboration with creative biotech industry, 
aiming at bringing these tests to the clinic.
Monitoring free DNA
With 10-100 billion fragments per milliliter of plasma, circulating cell-free DNA is an 
information-rich window into human physiology, for rapidly expanding applications in 
cancer diagnosis and therapy and prenatal diagnosis. More recently, cell-free donor-derived 
DNA (cfdDNA) has been proposed as a candidate marker for noninvasive diagnosis of graft 
injury. For female recipients of a graft from a male donor, donor-specific DNA can be 
identified using molecular assays targeting the Y chromosome. Single-nucleotide-
polymorphisms (SNPs) distributed across the entire genome do allow discriminating donor 
and recipient DNA molecules also regardless from their gender. A retrospective study on 43 
samples from 7 heart transplant patients showed a significant correlation between the 
fraction of cfdDNA and acute rejection episodes determined by endomyocardial biopsy 
[105]. A subsequent larger prospective-cohort study evaluated the performance of cfdDNA 
to measure allograft rejection in 565 plasma samples collected longitudinally from 65 adult 
and pediatric heart transplant recipients. Comparison to endomyocardial biopsy results (356 
samples) indicated that this approach can be used for the discrimination of rejecting and 
nonrejecting grafts and demonstrated the utility of the technique for the detection of acute 
cellular and antibody-mediated rejection in adult and pediatric heart transplant recipients, as 
well as in patients requiring a second heart transplant. These findings indicate that cfdDNA 
measurements have the potential to replace the endomyocardial biopsy and that these 
measurements can possibly be used also to predict acute rejection events and managing 
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immunosuppressant dosing. More recently, quantification of cfdDNA has been shown to 
identify acute rejection in lung transplant recipients [106], indicating that cfdDNA is a 
broadly applicable marker of graft injury that could be used also to monitor kidney graft 
status.
Conclusions
The development of noninvasive, accurate, and reliable assays to monitor alloreactivity in 
kidney transplant recipients could potentially lead to a new treatment paradigm in 
transplantation, with a conceivably safer, more tolerable, and cost-effective approach to 
immunosuppression. Over the last two decades, many assays have been developed to 
noninvasively quantify the level of alloreactivity in transplant patients. While some of these 
assays have been standardized across different laboratories [107, 108] and validated 
prospectively, no studies have formally tested whether or not these assays can be used as an 
alternative to, or in combination with an allograft biopsy to improve kidney transplant 
outcomes and to reduce the morbidity and mortality associated with over- and under-
immunosuppression. Similar to the ongoing European BIO-DRIM (BIOmarker-Driven 
personalized IMmunosuppression) consortium aiming at stratifying patients to high or low 
burden of immunosuppression according to pre-transplant donor-specific IFN-γ ELISPOT 
(CELLIMIN study; NCT02540395 ClinicalTrials.gov), future randomized clinical trials 
should assess whether titrating immunosuppressive therapy according to the results of one or 
some combination of these assays provides comparable results to the conventional approach 
based on serum creatinine levels, allograft biopsies and immunosuppressive drug levels. It is 
unlikely that a single immune-monitoring assay will provide adequate information 
representative of the complex pathophysiology of an individual's alloresponse. To overcome 
this major limitation, multiple tools could be combined to measure the immune response 
from different perspectives, including not only T and B cell alloreactivity, but also antibody 
profile and gene-expression pattern. A systems approach, where the focus is moved from 
analysis of individual cell types towards more integrated studies of the entire immune 
system, has been also proposed as a way to better measure alloreactivity and to personalize 
immunosuppressive therapy [109].
The task of translating immune-monitoring assays into day-to-day clinical practice is 
challenging, but will be the key to individualized immunosuppression in the future. Notably, 
the relevance of these assays extends beyond transplantation, since they could provide vital 
information also pertinent for the management of patients with autoimmune diseases.
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Biomarkers of T cell alloreactivity: common assays measuring the magnitude of direct or 
indirect activation of recipient T cells include the mixed lymphocyte reaction (left), cytokine 
ELISPOT (center), and detection of activation markers (right). In a mixed lymphocyte 
reaction (MLR) stimulated T cells are labeled with a fluorescent dye (left). The degree of 
fluorescence dilution is directly related to the extent of T cell proliferation. ELISPOT assays 
(center) use plate-bound antibody to detect cytokines (e.g. IFN-γ) secreted by an individual 
cell, manifest as a “spot” after use of a secondary antibody and enzymatic developer. 
Activation markers on alloreactive T cells (right) are expressed within 24–36 h after 
incubation with alloantigen, allowing for their identification. From: Transplant Reviews 
(2015) 29:53-59
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Comparison of HLA-specific Ab detection in serum, supernatant of ex-vivo expanded mBC 
cultures and HLA-sp mBC frequencies using a HLA-sp B-cell ELISPOT. A. Illustrative 
examples of 5 transplant candidates on the waiting list for kidney transplantation. Different 
possible information may be obtained when assessing the presence of HLA-sp B-cell 
sensitization when evaluating either the serum, the supernatants of ex-vivo expanded mBC 
cultures or mBC frequencies using a B-cell ELISPOT assay. While patient #1 did not show 
any evidence of anti-HLA sensitization in any compartment, patient 4 displayed anti-HLA 
sensitization by looking at either circulating anti-HLA Ab in the serum, HLA-sp mBC 
frequencies or the respective Ab in the supernatant of the expanded mBC culture. Of note, 
patients #2 and #5 showed circulating HLA-sp mBC using the B-cell Elispot assay but the 
respective Ab was not found neither in the supernatant of patient 5 nor in the serum of both 
patients. Alternatively, patient #3 showed a high HLA-sp mBC frequency as well as the 
respective Ab in the serum, but was not detected in the supernatant of the expanded mBC 
culture. B. In general, while sensitized transplant patients show a broad range of detectable 
HLA-sp mBC frequencies, which fit with the respective circulating anti-HLA Ab in the 
serum, an important proportion of patients the respective Ab assessed in the supernatant of 
the exvivo expanded mBC cultures might not be detectable, even using the highly sensitive 
solid-phase assays.
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Table 1
Options for monitoring T cell alloimmunity
Assay Description Pros/Cons
Mixed lymphocyte reaction (MLR) Lymphocytes from donor and recipient are combined 
and co-cultured; dye-dilution assays with CFSE are 
used to measure T cell proliferation in the recipient in 
response to donor antigen presentation
Pros: inexpensive, relatively easy to 
perform
Cons: poorly reproducible and time-
consuming; older technique, so limited 
data in tacrolimus era
ImmunKnow® Measures early response to stimulation by detecting 
intracellular ATP synthesis in CD4 cells selected from 
blood by monoclonal antibody coated magnetic beads; 
the amount of ATP present in stimulated blood 
specimens is a measure of lymphocyte activity
Pros: highly reproducible, rapid 
turnaround time, and relatively low cost
Cons: poor sensitivity/specificity, no 
large prospective studies to support its 
predictive value
Enzyme-linked immunospot (ELISPOT) Recipient lymphocytes are cultured in the presence of 
inactivated donor or third-party cells in tissue culture 
wells coated with a capture antibody against the 
cytokine of interest; plates are incubated for 18–24h; 
spots that develop represent a cells that had been primed 
to the stimulating antigen(s) in vivo, and are quantified 
using computerized plate readers
Pros: high throughput and functional 
readout; faster than MLR and amenable 
to standardization; multiple prospective 
studies to support its predictive value
Cons: expensive (compared to MLR) 
and labor-intensive
Abbreviations: CFSE – carboxyfluorescein diacetate succinimidyl ester; ATP – adenosine triphosphate
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Table 2






Assessment of HLA-specific B cells using fluorochrome-
conjugated HLA tetramers using flow cytometry. The HLA 
Tetramers are streptavidin-biotin complexes of 4 peptide-
loaded HLA molecules conjugated to a fluorescent protein. 
The tetramer-binding B cells can then be enumerated by flow 
cytometry
Pros: Easy detection of B cells harboring a HLA-sp B-
cell receptor.
Cons: Non-sp B-cell binding to fluorochomes; Low 
sensitivity to detect low frequencies (does not quantify 






Indirect assessment of HLA-sp mBC by measuring anti-
HLA antibodies in supernatants of ex-vivo expanded mBC 
cultures. Anti-HLA Ab are obtained from the supernatant of 
ex-vivo activated PBMC containing mBC during 6 days. 
Thereafter, Ab may be detected using a Luminex platform
Pros: Simple detection of anti-HLA Ab released by 
mBC.
Cons: Indirect quantification (assumes all ASC secrete a 
constant amount of IgG); Low sensitivity for low Ab 





Enumerates the frequency of HLA-specific mBC capable of 
secreting anti-HLA Ab. Uses PBMC that are polyclonally 
activated either through a cognate stimulation with anti-
CD40 mAB or CD40L, or using a TLR-derived stimuli 
together with a cytokine cocktail for 6 days. Afterwards, 
cells are seeded in IgG pre-coated ELISPOT wells and then 
multimerized biothynilated HLA class I or II molecules are 
added and IgG spots are visualized using an ELISPOT reader
Pros: Precise enumeration of HLA-sp mBC capable of 
secreting Ab (also low frequencies). Provides the 
frequency(strength) of alloresponse as it may be 
extrapolated to the total clonable mBC of a given 
individual.
Cons: Needs 6-day polyclonal stimulation; need of all 
synthetic HLA molecules to asses the whole HLA 
repertoire; expensive and labor-intensive
Abbreviations: mBC_ memory B cells; HLA-sp: Human Leukocyte Antigens-specific; Ab: antibody
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